IRCT20190701044062N4招募中3 期
Comparison of the therapeutic effect of empagliflozin with pioglitazone and vitamin E on non-alcoholic fatty liver in patients with type 2 diabetes
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 75 years（—）
- 性别
- All
入选标准
- •18 to 75 years old
- •BMI <45 kg/m2
- •A known case of type 2 diabetes used by metformin
- •A known case of non-alcoholic fatty liver
排除标准
- •History of hypoglycemia
- •liver disease Other than non-alcoholic fatty liver
- •Previous use of thiazolidinedione treatment?, immunomodulatory, antiobesity, anti-NASH glucagon-like peptide 1 agonists, sodium–glucose cotransporter 2 inhibitors, or vitamin E, amiodarone, tamoxifen, methotrexate In the last six months
- •severe heart, lung and kidney disease
- •Contraindications to the use of empagliflozin (drug allergy, recurrence of genital urinary tract infection, history of recent or previous gangrene)
- •Uncontrolled type 2 diabetes
- •Changes in diet and activity during the study
研究者
相似试验
尚未招募
3 期
Comparison of therapeutic effect of Empagliflozin (Gloripa) and Sitagliptin (Ziptin) on type 2 Diabetic patientsIRCT20200810048355N1Vice Chancellor for Research, Islamic Aazad University, Najafabad branch128
招募中
4 期
The effect of empagliflozin in patients with idiopathic edemaIdiopathic edema.Edema, unspecifiedR60.9IRCT20230314057712N1Ahvaz University of Medical Sciences70
招募中
3 期
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90
招募中
3 期
Evaluation of the effectiveness of Empagliflozin on metabolic factors and liver function testsIRCT20191209045671N3Semnan University of Medical Sciences60
招募中
2 期
The cardiac effect of pioglitazone and empagliflozin among diabetic patients with NAFLDCondition 1: Nonalcoholic fatty liver disease. Condition 2: Type 2 Diabetes. Condition 3: Cardiomyopathy.Nonalcoholic steatohepatitis (NASH)Type 2 diabetesK75.81CardiomyopathyIRCT20190122042450N5Iran University of Medical Sciences70